Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 251-823-9 | CAS number: 34090-76-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1995.12.6-1997.6.5
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study was conducted according to OECED guidelines and was performed under GLP.
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- Principles of method if other than guideline:
- not applicable
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Tetrahydromethylphthalic anhydride
- EC Number:
- 234-290-7
- EC Name:
- Tetrahydromethylphthalic anhydride
- Cas Number:
- 11070-44-3
- IUPAC Name:
- 3a-methyl-3a,4,5,6-tetrahydro-2-benzofuran-1,3-dione
- Details on test material:
- - Name of test material (as cited in study report): tetrahydromethyl-1,3-isobenzofurandione
- Analytical purity: 99.7%
- Purity test date: 1997-2
- Lot/batch No.: 2522
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles river Japan
- Age at study initiation: purchase at 9 weeks old, 1st. administration at 10 weeks old
- Weight at study initiation: male: 356.3-394.4g, female: 213.5-252.9g
- Fasting period before study: 18hr
- Housing: dosing period: stainless hanger gage, one animal/cage, mating period: polycarbonate gage with wood chip
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: one week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22-26°C
- Humidity (%): 45-65%
- Air changes (per hr): 13 times/hr
- Photoperiod (hrs dark / hrs light):12/12 AM07:00-PM07:00
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Justification for use and choice of vehicle (if other than water): Corn oil is used generally
- Concentration in vehicle: 0.6, 2 and 6w/v%
- Amount of vehicle (if gavage): 5mL/kg
- Lot/batch no. (if required): V5P5831, nakalai tesque Co. - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- no details given
- Duration of treatment / exposure:
- Males; for 49 days Females; from 14 days before mating to day 3 of lactation (38 days in total)
- Frequency of treatment:
- one administration/day
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0(Vehicle), 30, 100 and 300 mg/kg/day (in corn oil)
Basis:
actual ingested
- No. of animals per sex per dose:
- Doses is 0, 30, 100 and 300mg/kg. 12 animals per sex per dose.
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: oral, one of the identical exposure route for humans
- Positive control:
- no details given
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: one time per day
- Cage side observations: general symptom
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: male:two times/week
female: two times/ week at pre-mating period, in pregant period: day at 0, 4, 7,10, 14, 17 and 21, in lactation period: the day 0 and 4.
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
male: two times/week
female: two times/ week at pre-mating period, in pregnant period: day at 1, 4, 7,10, 14, 17 and 21, in lactation period: the day 1 and 4.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: after dosing period
- Anaesthetic used for blood collection: Yes (identity): Pentobarbital-Na i.p.
- Animals fasted: Yes
- How many animals: All of male
- Parameters checked in table (see below in remarks field) were examined.: WBC, RBC, Hb, Ht, PLT
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood:after dosing period (same time for HEMATOLOGY)
- Animals fasted: Yes
- How many animals:All of male
- Parameters checked in table (see below in remarks field) were examined.: TP, ALB, A/G, Bil, GOT, GPT, TGace, ALP, TG, PL, Giu, BUN, CRE, P, Ca, Na, K, Cl
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see below in remarks field)
HISTOPATHOLOGY: Yes (see below in remarks field) - Other examinations:
- no details given
- Statistics:
- no details given
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Three animals (male and female of 300mg/kg group and male of 30mg/kg group) is died by the accident at administration. Salivation was observed in 4-9(/12) animals at male 300 mg/kg on and after day 36. Salivation was observed immediately after administration, and continued about 30 min.
BODY WEIGHT AND WEIGHT GAIN
No stat. sig. difference from controls.
FOOD CONSUMPTION AND COMPOUND INTAKE
No stat. sig. difference from controls except one case (male 30 mg/kg, day 49, increase in consumption).
FOOD EFFICIENCY
Not examined
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study)
Not examined
OPHTHALMOSCOPIC EXAMINATION
Not examined
HAEMATOLOGY
No stat. sig. difference from controls.
CLINICAL CHEMISTRY
Males: Decrease of total cholesterol and BUN, increase of triglyceride at 300 mg/kg (p<0.05). Decrease of A/G ratio at 100 mg/kg (p<0.05). See Table 1 in overall remarks
URINALYSIS
Not examined
NEUROBEHAVIOUR
Not examined
ORGAN WEIGHTS
Male: Increase in kidney weight and adrenal weight at 100 mg/kg (absolute) (p<0.05), Increase in adrenal weight at 300 mg/kg (relative) (p<0.05)
Female: No stat. sig. difference from controls
See Table 2 in overall remarks
GROSS PATHOLOGY
hyperplasia(male:11/11, female 8/12) at forestomach mucosa (in 300mg/kg, terminal sacrifice)
HISTOPATHOLOGY: NON-NEOPLASTIC
See Table 3, Table 4, Table 5 in overall remarks.
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 30 other: mg/kg
- Sex:
- male
- Basis for effect level:
- other: hypertrophy of Gastric mucosa, 1/12
- Dose descriptor:
- NOEL
- Effect level:
- 100 other: mg/kg
- Sex:
- female
- Basis for effect level:
- other: hypertrophy of Gastric mucosa, 9/12
- Dose descriptor:
- NOAEL
- Effect level:
- 100 other: mg/kg
- Sex:
- male/female
- Basis for effect level:
- other: hypertrophy of Gastric mucosa, 12/12
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
NOAEL : Male = 100 mg/kg bw
Female = 100 mg/kg bw
Relative and/or absolute adrenal and/or kidney(s) weigh increase was observed in male 100 and/or 300mg/kg group, but no histopathological change was observed, so the author excluded this observation. Squeamous hyperplasia was observed in only one male of 100 mg/kg group, and 8/12 females of 300mg/kg.
Therefore, the NOAEL was determined to be 100mg/kg in both sex.
Applicant's summary and conclusion
- Conclusions:
- A NOAEL of 100 mg/kg bw/day was determined in a combined repeated dose/reproduction toxicity study (OECD 422) in rats based on decreased clinical chemistry parameters, changes in organ weights and inflammation of the forestomach mucosa.
- Executive summary:
Tetrahydromethylphthalic anhydride (MTHPA) was administered by gavage at doses of 0, 30, 100 and 300 mg/kg/day for 49 days in males and from 14 days before mating to day 3 of lactation in females (total number of 38 days). All animals survived at all treated group, except three animals died by accident (one female in 30 mg/kg, one male in 300 mg/kg and one female in 300 mg/kg group). Salivation was transiently observed in males of 300 mg/kg group at the day 36-49. Histopathological examination revealed squamous hyperplasia of the forestomach in both sexes of the 300 mg/kg group, epithelial vascular change, edema and cellular inflammation of the forestomach in males of the 300 mg/kg group, and erosion of the forestomach in females of 300 mg/kg group. There were no adverse effects on body weight and food consumption. There were no alterations related to tetrahydromethyl-1, 3-isobenzofuranedione on hematological examination. Decreased total cholesterol and BUN and increased triglyceride were observed in males of the 300 mg/kg. As a gross finding, mucosal thickening of the forestomach was found in both sexes of the 300 mg/kg group. Increased adrenal weights were observed in males of the 300 mg/kg group.
The major toxicity was inflammation of stomach mucosa. On the basis of this study, NOEL is 30mg/kg/day (male), 100mg/kg/day (female) and NOAEL is considered to be100 mg/kg/day for both sexes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.